by Peter Ciszewski | May 2, 2018
The U.S. Food and Drug Administration (FDA) approved the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) for the adjuvant treatment of patients with resected, stage III melanoma with BRAFV600 mutations. The combination is already approved for the...
by Peter Ciszewski | May 2, 2018
Jan-Anders Karlsson discusses Verona Pharma’s lead candidate, RPL554, as a potential therapy for cystic fibrosis (CF) patients and his company’s work with theCystic Fibrosis Trust. The Cystic Fibrosis Trust is the only UK-wide charity dedicated to...
by Peter Ciszewski | May 1, 2018
Positive results from the Fostamatinib in Thrombocytopenia (FIT) Phase 3 clinical program of fostamatinib disodium hexahydrate (Tavalisse) were published in the American Journal of Hematology this week for the treatment of adults with chronic immune thrombocytopenia...
by Peter Ciszewski | May 1, 2018
Chris Garabedian looks back to his time at Sarepta and his legacy...
by Peter Ciszewski | Apr 30, 2018
Stefan Weber, CEO of Newron Pharmaceuticals discusses his company’s clinical trial strategy for developing drugs for Rett Syndrome. Newron is focused on the development of novel therapies for patients with diseases of the central and peripheral nervous...
